Pharming Technologies B.V.

• An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients wi… Pending
  2025-524367-20-00 Phase II 7 countries 2-ISOPROPYL-3H-NAPHTHO(1,2-D)IMIDAZOLE-4,5-DIONE
• Leniolisib OLE for Immune Dysregulation in PID Recruiting
  2025-522444-40-00 Phase II 1 country LENIOLISIB PHOSPHATE
• Leniolisib for immune dysregulation in CVID Ended
  2024-517725-93-00 Phase II 1 country LENIOLISIB PHOSPHATE
• A trial to test the effect of leniolisib in children from 1 to 6 years of age with APDS Ended
  2022-502180-38-00 Phase III 2 countries LENIOLISIB PHOSPHATE
• A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 7… Ended
  2023-508880-61-00 Phase I (Other) 1 country LENIOLISIB PHOSPHATE
• An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharma… Ended
  2023-507134-25-00 Phase I (Other) 1 country
• An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic fun… Ended
  2023-508519-22-00 Phase I (Other) 2 countries
• Study of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Ended
  2024-515489-15-00 Phase III 1 country LENIOLISIB PHOSPHATE

Showing 1–8 of 8 trials